- Home
- SPFI vs SANA Comparison
SPFI vs SANA Comparison
Compare SPFI & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPFI
- SANA
- Stock Information
- Founded
- SPFI 1941
- SANA 2018
- Country
- SPFI United States
- SANA United States
- Employees
- SPFI N/A
- SANA N/A
- Industry
- SPFI Major Banks
- SANA Medicinal Chemicals and Botanical Products
- Sector
- SPFI Finance
- SANA Health Care
- Exchange
- SPFI Nasdaq
- SANA Nasdaq
- Market Cap
- SPFI 509.9M
- SANA 519.8M
- IPO Year
- SPFI 2019
- SANA 2021
- Fundamental
- Price
- SPFI $32.20
- SANA $1.65
- Analyst Decision
- SPFI Buy
- SANA Strong Buy
- Analyst Count
- SPFI 2
- SANA 5
- Target Price
- SPFI $40.50
- SANA $9.50
- AVG Volume (30 Days)
- SPFI 53.8K
- SANA 4.4M
- Earning Date
- SPFI 04-24-2025
- SANA 05-07-2025
- Dividend Yield
- SPFI 1.87%
- SANA N/A
- EPS Growth
- SPFI N/A
- SANA N/A
- EPS
- SPFI 2.92
- SANA N/A
- Revenue
- SPFI $190,870,000.00
- SANA N/A
- Revenue This Year
- SPFI $9.24
- SANA N/A
- Revenue Next Year
- SPFI $7.23
- SANA N/A
- P/E Ratio
- SPFI $11.03
- SANA N/A
- Revenue Growth
- SPFI N/A
- SANA N/A
- 52 Week Low
- SPFI $25.13
- SANA $1.26
- 52 Week High
- SPFI $40.91
- SANA $10.50
- Technical
- Relative Strength Index (RSI)
- SPFI 48.37
- SANA 42.97
- Support Level
- SPFI $30.36
- SANA $1.53
- Resistance Level
- SPFI $33.03
- SANA $1.92
- Average True Range (ATR)
- SPFI 1.37
- SANA 0.22
- MACD
- SPFI 0.07
- SANA 0.05
- Stochastic Oscillator
- SPFI 63.11
- SANA 59.09
About SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.